Advertisement

Topics

Auris Medical's Second Phase III Tinnitus Trial Disappoints

07:45 EDT 14 Mar 2018 | SCRIP

Auris Medical Holding's investigational tinnitus product, Keyzilen, has failed to meet its primary efficacy endpoint in an interim analysis of...

      

Related Stories

 

Original Article: Auris Medical's Second Phase III Tinnitus Trial Disappoints

NEXT ARTICLE

More From BioPortfolio on "Auris Medical's Second Phase III Tinnitus Trial Disappoints"

Advertisement
Quick Search
Advertisement
Advertisement